Drug Profile
Research programme: monoclonal antibodies - Genor Biopharma
Alternative Names: GB 214Latest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator Genor Biopharma
- Developer Genor Biopharma; Unknown
- Class Antineoplastics; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer; Metabolic disorders
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for preclinical development in Cancer in China (Parenteral)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Metabolic-disorders in China (Parenteral)
- 27 Jun 2019 Monoclonal antibodies - Genor Biopharma is available for licensing as of 27 Jun 2019. http://www.genorbio.com/en/index.jsp